공고 • Jul 09
The Craneware Group Introduces Medication Reimbursement Intelligence The Craneware Group introduced Medication Reimbursement Intelligence, its strategic framework for helping health systems manage medication reimbursement as a connected financial system. Medication reimbursement is changing. Evolving 340B reimbursement models, Medicare drug pricing requirements, third-party validation platforms, and increasing post-adjudication complexity are reshaping how medication revenue is validated, reconciled, and ultimately realized. What was once managed through a series of largely independent workflows has become a connected financial process that unfolds over time. Healthcare is entering an era where medication reimbursement must be managed as a financial system — not simply a series of reimbursement events. Drawing on decades of experience helping more than 2,000 hospitals and health systems improve financial performance, The Craneware Group has observed a fundamental shift in how medication reimbursement is managed. Health systems are being asked to navigate more reimbursement models, more validation requirements, and more financial dependencies than ever before. Many organizations have responded by adding workflows, tools, and staff. While necessary, those approaches often increase fragmentation across systems, teams, and timelines — limiting financial visibility, increasing audit exposure, and making it more difficult to understand financial performance across the reimbursement process. The pace of change across medication reimbursement now warrants a common framework for understanding and managing this growing complexity. Medication Reimbursement Intelligence is The Craneware Group's strategic framework for managing medication reimbursement as a connected financial system. Rather than responding to each new reimbursement requirement independently, Medication Reimbursement Intelligence brings together validation, submission, reconciliation, financial oversight, and evolving reimbursement models into a more integrated approach to financial management. It reflects how The Craneware Group believes health systems will increasingly need to manage medication reimbursement as reimbursement models continue to evolve. The Craneware Group is advancing Medication Reimbursement Intelligence through the continued development of Trisus OneLink - Medication, an evolving capability within the Trisus platform. Designed to support emerging reimbursement requirements, Trisus OneLink - Medication reflects The Craneware Group's commitment to helping health systems manage medication reimbursement through a more connected financial approach. The Craneware Group will continue the conversation during the 340B Coalition Summer Conference, where the company will engage healthcare leaders on the future of medication reimbursement and share how its ongoing investments are helping shape this emerging approach. Recent Insider Transactions • Jul 08
Co-Founder recently bought €117k worth of stock On the 6th of July, Keith Neilson bought around 9k shares on-market at roughly €12.89 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Keith's only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Jul 06
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €13.20, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 13x in the Healthcare Services industry in Europe. Total loss to shareholders of 46% over the past year. New Risk • Jul 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.9% average weekly change). 공고 • Jul 03
Craneware plc Provides Earnings Guidance for the Year Ended 30 June 2026 Craneware plc provided earnings guidance for the year ended 30 June 2026. The Board expects the Group's FY26 financial performance to be below market expectations, with revenue of USD 205 million - USD 208 million, broadly in line with FY25. This change results from the timing of eligible 340 B activity and the deferral of a small number of significant enterprise contracts, which are now expected to contribute during FY27. The final reported outcome remains subject to confirmation of eligible 340B activity recognised before the financial year end. The Group recognises a significant proportion of this revenue upon the customer receiving the benefit from these eligible 340B drugs, rather than at the point opportunities are identified. The financial impact of this reduced conversion only became apparent once the actual amount of 340B drugs shipped to the hospitals before year end became clear. 공고 • Mar 03
Craneware plc Declares Interim Dividend for the Six Months Ended 31 December 2025, Payable on 16 April 2026 Craneware plc announced the board has declared an interim dividend of 15.0 pence per ordinary share (20.25 cents per ordinary share) for the six months ended 31 December 2025 (H1 FY25: 13.5 pence per ordinary share (16.87 cents per ordinary share)). The interim dividend is payable on 16 April 2026 to those shareholders on the register as at 20 March 2026. The ex-dividend date is 19 March 2026. The interim dividend of 15 pence per share is capable of being paid in US dollars subject to a shareholder having registered to receive their dividend in US dollars under the Company's Dividend Currency Election, or who has registered to do so by the close of business on 20 March 2026. The exact amount to be paid will be calculated by reference to the exchange rate to be announced on 20 March 2026. 
